" class="no-js "lang="en-US"> SciSparc Seek Patent Application for Treatment of Depression
Monday, June 05, 2023

Breaking News

Providence Therapeutics Announces Partnership with University Health Network (UHN) for mRNA Therapeutic Discovery and Development Affini-T Therapeutics Appoints Industry Veteran Thaminda Ramanayake, M.S., MBA, as Chief Business Officer Feinstein Institutes Bioelectronic Medicine Researchers Stimulate Vagus Nerve to Reduce Bleeding in Hemophilia Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in Lupus Nephritis Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency CANbridge Announces Marketing Approval of CAN108 in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome GC Biopharma Receives a Business License for the Construction of a Plasma Fractionation Plant and Technology Transfer in Indonesia Cytovation Raises $8 Million in Series A Extension Financing Round for Clinical Advancement of CyPep-1, a First-in-class Targeted Tumor Membrane Immunotherapy FUJIFILM Cellular Dynamics Introduces First-of-its-Kind Human iPSC-derived Blood-Brain Barrier Isogenic Kit Landmark Bio Partners With InnDura Therapeutics to Advance Immune Cell Therapy Research
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression | MTA

April 21 2023

SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression

SciSparc, a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine, a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, an additional provisional patent application was filed by Clearmind with the United States Patent and Trademark Office, refering to the protection of the unique combination of MEAI and SciSparc’s Palmitoylethanolamide for the treatment of depression.

Under this collaboration, three other patent applications have been filed by Clearmind with the USPTO for the combination of SciSparc’s PEA with Clearmind’s MEAI compound (5-methoxy-2-aminoindane) for the treatment of alcohol use disorder, treatment of cocaine addiction and treatment of obesity and its related metabolic disorders. An additional six patent applications have been filed for the combination of SciSparc’s PEA and lysergic acid diethylamide (LSD), psilocybin, and N,N-dimethyltryptamine (DMT), 3,4 methylenedioxymethamphetamine (MDMA), ibogaine and ketamine.

  1. Providence Therapeutics Announces Partnership with University Health Network (UHN) for mRNA Therapeutic Discovery and Development

    News

     Read more
  2. Affini-T Therapeutics Appoints Industry Veteran Thaminda Ramanayake, M.S., MBA, as Chief Business Officer

    Appointments

     Read more
  3. Feinstein Institutes Bioelectronic Medicine Researchers Stimulate Vagus Nerve to Reduce Bleeding in Hemophilia

    Diseases

     Read more
  4. Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in Lupus Nephritis

    Drug Development

     Read more
  5. Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency

    Drug Development

     Read more
More On